Cargando…

Epitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase

Staphylococcus aureus represents a serious infectious threat to global public health and a vaccine against S. aureus represents an unmet medical need. We here characterise two S. aureus vaccine candidates, coproporphyrinogen III oxidase (CgoX) and triose phosphate isomerase (TPI), which fulfil essen...

Descripción completa

Detalles Bibliográficos
Autores principales: Klimka, Alexander, Mertins, Sonja, Nicolai, Anne Kristin, Rummler, Liza Marie, Higgins, Paul G., Günther, Saskia Diana, Tosetti, Bettina, Krut, Oleg, Krönke, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813823/
https://www.ncbi.nlm.nih.gov/pubmed/33462229
http://dx.doi.org/10.1038/s41541-020-00268-2
_version_ 1783637936077537280
author Klimka, Alexander
Mertins, Sonja
Nicolai, Anne Kristin
Rummler, Liza Marie
Higgins, Paul G.
Günther, Saskia Diana
Tosetti, Bettina
Krut, Oleg
Krönke, Martin
author_facet Klimka, Alexander
Mertins, Sonja
Nicolai, Anne Kristin
Rummler, Liza Marie
Higgins, Paul G.
Günther, Saskia Diana
Tosetti, Bettina
Krut, Oleg
Krönke, Martin
author_sort Klimka, Alexander
collection PubMed
description Staphylococcus aureus represents a serious infectious threat to global public health and a vaccine against S. aureus represents an unmet medical need. We here characterise two S. aureus vaccine candidates, coproporphyrinogen III oxidase (CgoX) and triose phosphate isomerase (TPI), which fulfil essential housekeeping functions in heme synthesis and glycolysis, respectively. Immunisation with rCgoX and rTPI elicited protective immunity against S. aureus bacteremia. Two monoclonal antibodies (mAb), CgoX-D3 and TPI-H8, raised against CgoX and TPI, efficiently provided protection against S. aureus infection. MAb-CgoX-D3 recognised a linear epitope spanning 12 amino acids (aa), whereas TPI-H8 recognised a larger discontinuous epitope. The CgoX-D3 epitope conjugated to BSA elicited a strong, protective immune response against S. aureus infection. The CgoX-D3 epitope is highly conserved in clinical S. aureus isolates, indicating its potential wide usability against S. aureus infection. These data suggest that immunofocusing through epitope-based immunisation constitutes a strategy for the development of a S. aureus vaccine with greater efficacy and better safety profile.
format Online
Article
Text
id pubmed-7813823
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Nature Publishing Group UK
record_format MEDLINE/PubMed
spelling pubmed-78138232021-01-25 Epitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase Klimka, Alexander Mertins, Sonja Nicolai, Anne Kristin Rummler, Liza Marie Higgins, Paul G. Günther, Saskia Diana Tosetti, Bettina Krut, Oleg Krönke, Martin NPJ Vaccines Article Staphylococcus aureus represents a serious infectious threat to global public health and a vaccine against S. aureus represents an unmet medical need. We here characterise two S. aureus vaccine candidates, coproporphyrinogen III oxidase (CgoX) and triose phosphate isomerase (TPI), which fulfil essential housekeeping functions in heme synthesis and glycolysis, respectively. Immunisation with rCgoX and rTPI elicited protective immunity against S. aureus bacteremia. Two monoclonal antibodies (mAb), CgoX-D3 and TPI-H8, raised against CgoX and TPI, efficiently provided protection against S. aureus infection. MAb-CgoX-D3 recognised a linear epitope spanning 12 amino acids (aa), whereas TPI-H8 recognised a larger discontinuous epitope. The CgoX-D3 epitope conjugated to BSA elicited a strong, protective immune response against S. aureus infection. The CgoX-D3 epitope is highly conserved in clinical S. aureus isolates, indicating its potential wide usability against S. aureus infection. These data suggest that immunofocusing through epitope-based immunisation constitutes a strategy for the development of a S. aureus vaccine with greater efficacy and better safety profile. Nature Publishing Group UK 2021-01-18 /pmc/articles/PMC7813823/ /pubmed/33462229 http://dx.doi.org/10.1038/s41541-020-00268-2 Text en © The Author(s) 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Article
Klimka, Alexander
Mertins, Sonja
Nicolai, Anne Kristin
Rummler, Liza Marie
Higgins, Paul G.
Günther, Saskia Diana
Tosetti, Bettina
Krut, Oleg
Krönke, Martin
Epitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase
title Epitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase
title_full Epitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase
title_fullStr Epitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase
title_full_unstemmed Epitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase
title_short Epitope-specific immunity against Staphylococcus aureus coproporphyrinogen III oxidase
title_sort epitope-specific immunity against staphylococcus aureus coproporphyrinogen iii oxidase
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7813823/
https://www.ncbi.nlm.nih.gov/pubmed/33462229
http://dx.doi.org/10.1038/s41541-020-00268-2
work_keys_str_mv AT klimkaalexander epitopespecificimmunityagainststaphylococcusaureuscoproporphyrinogeniiioxidase
AT mertinssonja epitopespecificimmunityagainststaphylococcusaureuscoproporphyrinogeniiioxidase
AT nicolaiannekristin epitopespecificimmunityagainststaphylococcusaureuscoproporphyrinogeniiioxidase
AT rummlerlizamarie epitopespecificimmunityagainststaphylococcusaureuscoproporphyrinogeniiioxidase
AT higginspaulg epitopespecificimmunityagainststaphylococcusaureuscoproporphyrinogeniiioxidase
AT gunthersaskiadiana epitopespecificimmunityagainststaphylococcusaureuscoproporphyrinogeniiioxidase
AT tosettibettina epitopespecificimmunityagainststaphylococcusaureuscoproporphyrinogeniiioxidase
AT krutoleg epitopespecificimmunityagainststaphylococcusaureuscoproporphyrinogeniiioxidase
AT kronkemartin epitopespecificimmunityagainststaphylococcusaureuscoproporphyrinogeniiioxidase